SynthesisThe Journal of international medical research2026
Efficacy evaluation of novel targeted drugs in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis based on multiple sets of clinical data.
Synthesis in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo evaluate the efficacy and safety of novel targeted drugs in patients with human epidermal growth factor receptor 2-positive breast cancer and their impact on clinical outcomes, including overall survival and progression-free survival.MethodsThis systematic review was registered with PROSPERO (CRD420261383276). A systematic search of PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov was conducted for randomized controlled trials and prospective cohort studies published between January 2000 and March 2024. Participants were adult females diagnosed with human epidermal growth factor receptor 2-positive breast cancer who were treated with novel agents (e.g. T-DXd, margetuximab, and tucatinib). Primary outcomes included overall survival, progression-free survival, objective response rate, and disease control rate. Statistical analyses were performed using RevMan 5.4 and Stata 16.0 with random-effects models.ResultsEight studies were included from 2567 identified records. Novel human epidermal growth factor receptor 2-targeted drugs significantly improved overall survival (hazard ratio = 0.73, 95% confidence interval: 0.68-0.79) and progression-free survival (hazard ratio = 0.65, 95% confidence interval: 0.60-0.71) compared with standard treatments. The objective response rate (50% vs. 35%) and disease control rate (80% vs. 60%) were also significantly higher in the novel drug group. Subgroup analyses revealed greater benefits among patients with hormone receptor-negative disease (progression-free survival, hazard ratio = 0.58, 95% confidence interval: 0.50-0.67) and those with brain metastases (progression-free survival, hazard ratio = 0.52, 95% confidence interval: 0.45-0.60). Furthermore, novel drugs were associated with lower incidences of cardiotoxicity (5% vs. 15%) and gastrointestinal reactions (10% vs. 25%).ConclusionsNovel targeted drugs demonstrate superior efficacy and a more favorable safety profile than traditional therapies in patients with human epidermal growth factor receptor 2-positive breast cancer. These findings provide a clinical basis for optimizing individualized treatment, particularly for high-risk subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.